John L. Flavin's most recent trade in Pyxis Oncology Inc was a trade of 36,979 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 31, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Pyxis Oncology Inc | John L. Flavin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
Pyxis Oncology Inc | L. Flavin John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 35,219 | 413,015 | - | 0 | Common Stock | |
Pyxis Oncology Inc | John L. Flavin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 139,355 | 377,796 | - | 0 | Common Stock | |
Pyxis Oncology Inc | John L. Flavin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66,831 | 238,441 | - | 0 | Common Stock | |
Pyxis Oncology Inc | John L. Flavin | Director | 13 Oct 2021 | 15,190 | 0 | - | - | Series B Convertible Preferred Stock | ||
Pyxis Oncology Inc | John L. Flavin | Director | 13 Oct 2021 | 2,388 | 171,610 | - | - | Common Stock | ||
Pyxis Oncology Inc | John L. Flavin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 42,191 | 42,191 | - | - | Stock Option (Right to buy) |